Open access
Aug 2026
Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma
Glioblastoma (GBM) is the most aggressive primary brain tumor with limited therapeutic options and extremely poor prognosis. Aberrant activation of the receptor tyrosine kinase MET drives tumor progression, therapeutic resistance, and reduced survival, particularly in the mesenchymal GBM subtype. Given its crucial role...
Yun-Zhan Li, Hanif Khan, Şeyma Demirsoy et al.
· International Journal of Mol... · 0 citations